Statin tolerability: In defence of placebo-controlled trials

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Statin intolerance presents a significant barrier to effective lipid-lowering therapy.
• Many patients discontinue statins or require lower doses due to perceived adverse events, leading to a diagnosis of statin intolerance.

Purpose of the Study:

• To evaluate statin tolerability by comparing withdrawal rates due to adverse events between statin and placebo groups in cardiovascular outcome trials.
• To examine common arguments used to dismiss the validity of safety and tolerability data from statin clinical trials.

Main Methods:

• Analysis of withdrawal rates due to adverse events in statin cardiovascular outcome trials.
• Focus on patient populations with advanced disease and complex medical histories, who are potentially more susceptible to adverse effects.
• Critical examination of existing arguments regarding the interpretation of clinical trial data on statin safety and tolerability.

Main Results:

• Withdrawal rates due to adverse events were consistently similar between statin and placebo groups in trials involving patients with advanced disease and complex medical histories.
• The study found no evidence to support claims that data from statin cardiovascular outcome trials are not applicable to clinical practice.

Conclusions:

• The absence of intolerance signals in clinical trials suggests that clinical statin intolerance is frequently driven by the nocebo effect, where patients attribute background symptoms to statins.
• Over 90% of patients who previously discontinued statins due to adverse events tolerated them upon re-challenge.
• Novel therapies like PCSK9 inhibitors are valuable adjuncts to statin therapy but should not typically replace statins.